Clinical Trials Logo

Neoplasms, Colorectal clinical trials

View clinical trials related to Neoplasms, Colorectal.

Filter by:

NCT ID: NCT00540943 Completed - Clinical trials for Neoplasms, Colorectal

Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer

Start date: July 13, 2007
Phase: Phase 1
Study type: Interventional

Subjects will be entered into cohorts of 3 for the dose escalation phase so that the maximum tolerated dose can be determined. 18 additional patients will be recruited once the maximum tolerated dose (MTD) is determined for disease assessment.

NCT ID: NCT00536809 Completed - Clinical trials for Neoplasms, Colorectal

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

Start date: September 26, 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activity of the combination of drugs in subjects with previously untreated advanced or metastatic colorectal cancer.

NCT ID: NCT00478634 Completed - Colorectal Cancer Clinical Trials

A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Start date: May 2007
Phase: Phase 1
Study type: Interventional

This study will assess the safety of RAD001 when given together with cetuximab and irinotecan

NCT ID: NCT00387387 Completed - Clinical trials for Neoplasms, Colorectal

Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Start date: October 20, 2006
Phase: Phase 1
Study type: Interventional

This study will test the safety of treating colorectal cancer with a combination of drugs. The current standard treatments of FOLFOX6 or CapeOx will be give in combination with the GSK investigational drug pazopanib.